CLINICAL_TRIALS trial_result · 2025-12-19

Clinical Trial Update: A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age [Phase 3]

A Phase 3 pediatric trial evaluating fremanezumab for preventing chronic migraine in participants aged 6 to 17 has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2025-12-19